Monday, February 28, 2011 6:34:57 PM
Shares of partners Santarus Inc. (SNTS 3.18, -0.01, -0.21%) and Netherlands-based Pharming Group N.V. (NL:PHARM 0.15, -0.04, -18.62%) took a hit Monday on news that U.S. regulators have refused to accept their market application for the drug Rhucin due to insufficient data.
The companies are seeking to have Rhucin approved to treat the rare condition hereditary angioedema. Santarus and Pharming intend to meet regulators to discuss what will be needed to re-file the application.
Pharming shares sank almost 20% to 15 cents, while Santarus shares dipped 8% to $2.99.
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM
CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • CBDL • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM